Michael F. MacLean

Michael F. MacLean, listed as finance chief, appears in our data through filings on Avidity Biosciences, Inc. shares, published by SEC (Form 4). We count 17 filings; the first trade dates from 20 January 2023 and the latest from 27 February 2026.

The open-market record consists of 8 sales worth €3.2M, with no purchase. The rest of the record consists of 5 share grants and 3 option exercises. 2026 to date brings no purchases and 2 sales.

Most recently, on 27 February 2026, the filings show a transaction in Avidity Biosciences, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.